You are here

  • Home
  • Archive
  • Volume 68, Issue 3
  • CD1d expression in renal cell carcinoma is associated with higher relapse rates, poorer cancer-specific and overall survival

Article Text

Article menu

This article has a correction. Please see:

Download PDFPDF

Original article
CD1d expression in renal cell carcinoma is associated with higher relapse rates, poorer cancer-specific and overall survival
  1. Tsung Wen Chong1,
  2. Fera Yiqian Goh1,
  3. Mei Yi Sim1,
  4. Hong Hong Huang1,
  5. Daw Aye Aye Thike2,
  6. Weng Khong Lim3,4,
  7. Bin Tean Teh3,4,5,
  8. Puay Hoon Tan2
  1. 1Department of Urology, Singapore General Hospital, Singapore, Singapore
  2. 2Department of Pathology, Singapore General Hospital, Singapore, Singapore
  3. 3Laboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre, Singapore, Singapore
  4. 4Division of Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore, Singapore
  5. 5Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
  1. Correspondence to Dr Tsung Wen Chong, Department of Urology, Singapore General Hospital, 20 College Road, Singapore 169856, Singapore; gurctw{at}sgh.com.sg

Abstract

Aims We hypothesised that CD1d expression in renal cell carcinoma (RCC) may play a role in modifying the host immune response. Our aims were to investigate the expression of CD1d and to correlate this with histopathology and clinical outcomes in a cohort study of patients with RCC.

Methods Gene expression and tissue microarray studies on a panel of RCC tissue were performed. Clinicopathological correlation was analysed using χ2/Fisher's exact test. Relapse-free survival, cancer-specific survival and overall survival were calculated for both CD1d high and low expressors. Survival outcomes were estimated with the Kaplan–Meier method and compared using Cox regression analysis.

Results Gene expression microarray showed significant expression of CD1d in RCC versus normal renal tissue. By immunohistochemistry, we found that CD1d expression significantly associated with tumour stage/grade, higher relapse rates, poorer cancer-specific and overall survival.

Conclusions CD1d expression on RCC correlated with aggressive disease and poorer clinical outcomes.

  • IMMUNOHISTOCHEMISTRY
  • IMMUNOLOGY
  • UROPATHOLOGY

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

https://doi.org/10.1136/jclinpath-2014-202735

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Linked Articles

    • Correction
      Correction
      BMJ Publishing Group Ltd and Association of Clinical Pathologists
      Journal of Clinical Pathology 2015; 68 912-912 Published Online First: 19 Oct 2015. doi: 10.1136/jclinpath-2014-202735corr1